699 filings
Page 3 of 35
8-K
lsmseu rzm
14 Aug 17
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results
12:00am
EFFECT
s5bf6xm2ve4hklrtp
4 Aug 17
Notice of effectiveness
12:00am
CORRESP
wdxk1upmijn8kgi7w1
1 Aug 17
Correspondence with SEC
12:00am
UPLOAD
v1wni5
31 Jul 17
Letter from SEC
12:00am
8-K
ty1f70
26 Jul 17
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
12:00am
RW
ibyaj7 cvdg78zbsbae
25 Jul 17
Registration withdrawal request
12:00am
8-K
qp6i6x
21 Jul 17
Other Events
12:00am
8-K
skaxr0a
17 Jul 17
Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
12:00am
8-K
sdoqv72 bvwjoq
16 Jun 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
p3jtrrvjm
31 May 17
Departure of Directors or Certain Officers
12:00am
8-K
kchtyx0utymh1j9l ua6
22 May 17
Other Events
12:00am
424B5
x5tbooolmrwd
18 May 17
Prospectus supplement for primary offering
12:00am
424B5
37pczxjsu5alye
18 May 17
Prospectus supplement for primary offering
12:00am
8-K
mg99dy9tet
17 May 17
REPROS THERAPEUTICS CORPORATE PRESENTATION MAY 2017 Dedicated to Treating Male and Female Reproductive Disorders
12:00am
8-K
ghvofzzv
9 May 17
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results
12:00am